Finally a good update (as it contains information to more than...

Finally a good update (as it contains information to more than just one matter):

• Extended cash runway

• Trials not affected by COVID-19

• "Additionally, Cynata is responding to enquiries and is in active discussions with international pharmaceutical

companies and other parties about the potential of its Cymerus MSCs to be a useful adjunct in the management of
patients with serious and ongoing issues associated with COVID-19 infection. COVID-19 has been shown to cause
conditions including acute respiratory distress syndrome (ARDS), sepsis and cytokine release syndrome (CRS),
indications where Cynata has previously demonstrated utility of its Cymerus MSCs in preclinical studies. Of direct
relevance are observations in these preclinical studies that Cynata’s Cymerus MSCs significantly reduce levels of proinflammatory cytokines and increase both anti-inflammatory proteins and regulatory T cells1".

"is responding" = was being approached?

"Therefore, MSC therapy inhibiting the overactivation of the immune system and promoting endogenous repair by improving the lung microenvironment after the SARS-CoV-2 infection found in this study is striking."
"In the study by Dr. Zhao and collaborators, seven
patients with COVID-19 pneumonia displayed improved
functional outcomes and recovered after an intravenous
administration of clinical-grade human MSCs [1]. The
chosen patients were positive for SARS-CoV-2, with one
displaying critically severe type, 4 exhibiting severe
types, and the other 2 showing common types of the
syndrome. An additional three patients with severe types
were enrolled for placebo control. Before MSC infusion,
all patients displayed high fever, shortness of breath, low
oxygen saturation, and pneumonia. The patients received
1 million MSCs per kilogram body weight when their
symptoms were getting worse and were observed closely
for 14 days. Notably, the study found that virtually all
symptoms subsided by 2-4 days after receiving MSC
infusion with no apparent adverse effects. Chest CT
imaging demonstrated that chest pneumonia infiltration
was significantly subsided. Also, the majority of patients
showed negative results for the SARS-CoV-2 nucleic acid
test over a week or two after MSC infusion. The overall
improvement was quite extraordinary for an elderly
patient in a critical condition after the infection [1]."
http://www.aginganddisease.org/EN/10.14336/AD.2020.0301#1

• Our OA trial is "in the final stages toward commencement, with the expectation

that this major trial will begin enrolling patients in the near term."
I found the below regarding the University of Sydney Clinical Trial Procedures and it seems that they did in fact tick all boxes and once the ethic committee signs of on the trial and with the screening already started, they can start recruiting.
"The required steps, which may be commenced in any order and may be
undertaken in parallel."
https://www.sydney.edu.au/policies/showdoc.aspx?recnum=PDOC2016/427&RendNum=0